INTRODUCTION
Rapid and stable modification of neural circuits is thought to underlie learning and memory. The signaling pathways that mediate this circuit plasticity are thought to drive both functional and structural changes in existing synapses, as well as the addition of new synapses. In the mammalian cerebral cortex, the addition of new synapses during experience-dependent plasticity has been associated with the addition of dendritic spines (Comery et al., 1995; Knott et al., 2002; Trachtenberg et al., 2002) . Moreover, the appearance of new persistent spines has been associated with novel sensory experience and learning new tasks (Hofer et al., 2009; Holtmaat et al., 2006; Roberts et al., 2010; Xu et al., 2009; Yang et al., 2009) . While new dendritic spines tend to be short lived (Trachtenberg et al., 2002) , those that stabilize are capable of rapid functional maturation (Zito et al., 2009) . These data support that the formation and stabilization of new dendritic spines is a key structural component underlying synaptic plasticity.
Although the detailed signaling mechanisms that initiate the outgrowth of new dendritic spines during experience-dependent plasticity remain poorly defined, there is strong evidence that increased neural activity can enhance new spine growth (Engert and Bonhoeffer, 1999; Kwon and Sabatini, 2011; Maletic-Savatic et al., 1999; Papa and Segal, 1996) . Multiple studies demonstrate that activity-induced spine outgrowth is dependent on NMDA receptor signaling (Engert and Bonhoeffer, 1999; Kwon and Sabatini, 2011; Maletic-Savatic et al., 1999) . What further signaling mechanisms act downstream of activity to initiate new spine growth? Over the past decade, evidence has been rapidly accumulating that the proteasome is an important mediator of activity-induced neuronal signaling (Bingol and Sheng, 2011; Tai and Schuman, 2008) . Neural activity regulates proteasomal activity (Bingol and Schuman, 2006; Djakovic et al., 2009) , resulting in alterations in the abundance of synaptic proteins (Ehlers, 2003) . Moreover, activity-dependent changes in the rate of proteasome-mediated degradation can occur rapidly and can be localized to a small region of the stimulated dendrite (Bingol and Schuman, 2006; Djakovic et al., 2009) . These data suggest that the proteasome is a key downstream mediator of localized activity-dependent neuronal signaling and therefore may play a role in activity-dependent spinogenesis.
In this study, we used pharmacological and genetic manipulations in combination with time-lapse two-photon microscopy and two-photon glutamate uncaging to investigate the role of the proteasome in new spine growth on dendrites of hippocampal pyramidal neurons. We show that acute inhibition of the proteasome rapidly reduces the rate of spine outgrowth. Synaptic activity, NMDA receptors, and CaMKII, but not PKA, are upstream regulators of proteasome-mediated spine outgrowth, which is dependent upon interaction between CaMKII and the GluN2B subunit of the NMDA receptor. The S120 residue of the Rpt6 proteasomal subunit is critical for proteasome-dependent spine outgrowth in individual neurons, indicating that the proteasome acts postsynaptically and in a cell-autonomous manner to regulate spine outgrowth. Our data support a model in which synaptic activity promotes spine outgrowth via an NMDA receptor-and CaMKII-mediated regulation of local proteasomal degradation.
RESULTS

Proteasome Inhibition Acutely Reduces New Spine Outgrowth
To determine whether the proteasome plays a role in regulating the growth of new dendritic spines, we used pharmacological manipulations and time-lapse two-photon microscopy to measure the effect of acute inhibition of the proteasome on the rate of spine outgrowth. Hippocampal pyramidal neurons in organotypic slice cultures were transfected with enhanced green fluorescent protein (EGFP) and imaged using a two-photon microscope. Dendrites of EGFP-expressing CA1 neurons were imaged at 15 or 20 min intervals before and after treatment with drugs or vehicle ( Figure 1A) .
Treatment with the proteasome inhibitor MG132 (10 mM) reduced the rate of spine outgrowth to half (52% ± 12%) that of vehicle-treated control cells (100% ± 13%; p < 0.05; Figure 1B ). Because MG132 inhibits the activity of calpains as well as the proteasome, we confirmed our findings with the proteasome-specific inhibitor lactacystin. Treatment with lactacystin (10 mM) reduced the rate of spine outgrowth by 68% (32% ± 7%) as compared to vehicle control (100% ± 13%; p < 0.001; Figure 1C ). Similar reductions in spine out- growth were observed for both apical and basal dendrites (see Figure S1A available online). The reduction in spine outgrowth due to lactacystin was not significantly different than that due to MG132 (p = 0.2), suggesting that reduced spine outgrowth in the presence of MG132 is specifically due to inhibition of the proteasome. To ensure that the effect of proteasome inhibition was saturated, we doubled the concentration of lactacystin in the bath. Treatment with 20 mM lactacystin resulted in a 62% reduction in new spine growth (38% ± 7%), which was not significantly different than that observed in the presence of 10 mM lactacystin (p = 0.6; Figure 1C ), suggesting that spine outgrowth observed in the presence of lactacystin is proteasome independent.
A variety of cellular processes, including the endocytosis of transmembrane proteins, are dependent on proteolysisindependent ubiquitination (Acconcia et al., 2009; Hicke, 2001) . It is conceivable that a drop in free ubiquitin levels caused by proteasome inhibition (Schubert et al., 2000) could interfere with new spine growth via a secondary effect on endocytosis. We think that this is unlikely for two reasons. First, the reduction in new spine growth in response to proteasomal inhibition was very rapid; we observed a significant reduction in spine outgrowth within 5 min of drug application (p < 0.05; Figure 1D ). Second, a reduction in endocytosis might be expected to cause an increase in spine volume or density, as spine volume and stability are tightly linked to glutamate receptor content (Hsieh et al., 2006; Matsuzaki et al., 2004) . Within the time course of our experiments, we saw no change in spine volume or spine density in response to MG132 treatment (data not shown). The lack of change in spine density might appear inconsistent with the significantly decreased rate of spine addition in response to MG132; however, because most new spines are transient, reduced new spine outgrowth is expected to be accompanied by reduced spine loss, which we observed ( Figure S1B ).
Our data suggest that the reduction in new spine growth in response to proteasome inhibitors is due to acute inhibition of proteasomal activity.
Synaptic Activity Promotes New Spine Growth in a Proteasome-Dependent Manner Because synaptic activity can enhance both spine outgrowth (Engert and Bonhoeffer, 1999; Kwon and Sabatini, 2011) and the activity of the proteasome (Bingol and Schuman, 2006; Djakovic et al., 2009) , we next examined whether the proteasome plays a role in regulating activity-induced spine outgrowth ( Figure 2 ). Treatment with bicuculline (30 mM), which strongly enhanced synaptic activity ( Figure S2 ), resulted in a 69% increase in spine outgrowth (169% ± 16%) relative to vehicletreated controls (100% ± 13%; p < 0.05; Figures 2A and 2B ). The activity-induced increase in spine outgrowth was blocked by concurrent application of MG132 (10 mM), which instead caused a 34% decrease in spine outgrowth (66% ± 9%; p < 0.05; Figure 2B ), an effect that was indistinguishable from treatment with MG132 alone (p = 0.4). Thus, we conclude that proteasomal degradation is necessary for activity-induced spine outgrowth.
Because bicuculline alters global neural activity levels in our slice cultures, we chose also to use a more localized dendritic stimulus to examine the role of the proteasome in activitydependent spine outgrowth. A recent study using focal photolysis of caged glutamate demonstrated that direct glutamatergic stimulation of the dendrite can result in rapid spine outgrowth (Kwon and Sabatini, 2011) . Using two-photon uncaging of MNI-glutamate and pharmacological inhibition, we examined whether proteasomal degradation is necessary for glutamate uncaging-induced spine outgrowth ( Figures 2C and 2D ). We found that uncaging-induced spine outgrowth was significantly reduced in the presence of lactacystin (15% success rate) as compared to control (36% success rate; p < 0.05; Figure 2E ). This local activity-dependent spine outgrowth occurred with high spatial specificity such that most new spines (>87%) grew within 1 mm of the uncaging location. These results further demonstrate that proteasomal degradation acts to facilitate activity-dependent spine outgrowth in a spatially precise manner. Signaling through the NMDA Receptor Is Required for Proteasome-Dependent Dendritic Spine Outgrowth Stimulation of proteasomal degradation by neural activity has been shown to occur via the action of NMDA receptors (Bingol and Schuman, 2006; Djakovic et al., 2009 ), which also have been shown to play a role in activity-induced outgrowth of new spines (Engert and Bonhoeffer, 1999; Kwon and Sabatini, 2011) . Indeed, NMDA treatment increased the degradation of a fluorescent proteasome substrate in dendrites of CA1 pyramidal neurons in our cultured hippocampal slices ( Figure S3 ). We therefore investigated the role of the NMDA receptor in proteasome-dependent new spine growth ( Figures 2F and 2G) .
Inhibition of NMDA receptors with CPP (30 mM) resulted in a 62% reduction in spine outgrowth (38% ± 5%) as compared to vehicle control (100% ± 9%; p < 0.001; Figure 2G ), suggesting that baseline spine outgrowth is partially activity dependent. The reduction in spine outgrowth observed after CPP treatment was not different than that after lactacystin treatment (p = 0.3), suggesting that the NMDA receptor and the proteasome act in the same pathway to induce new spine growth. To test this idea, we simultaneously applied lactacystin and CPP. Simultaneous treatment with both lactacystin and CPP resulted in a 53% reduction in new spine growth (47% ± 9%) as compared to vehicle control (100% ± 8%; p < 0.05; Figure 2G ), a decrease that was not different than that observed in response to CPP (p = 0.7) or lactacystin (p = 0.3; Figure 1C) alone. Our data demonstrate that the NMDA receptor and the proteasome act in the same pathway to promote new spine growth in response to neural activity.
Mutation of Serine 120 to Alanine in the Rpt6
Proteasomal Subunit Blocks Activity-Induced New Spine Growth Which signaling mechanisms act downstream of the NMDA receptor and the proteasome to translate neural activity into enhanced spine growth? Recent work has identified serine 120 of the Rpt6 proteasomal subunit as an important target site for CaMKII phosphorylation (Bingol et al., 2010; Djakovic et al., 2012) . To test whether the S120 residue of Rpt6 is necessary for activity-dependent spine outgrowth, we used time-lapse imaging to monitor new spine growth on dendrites of neurons transfected with EGFP alone or with both EGFP and hemagglutinin (HA)-tagged Rpt6-WT or Rpt6-S120A ( Figure 3A) . Expression levels were equivalent for both of the HA-tagged Rpt6 constructs, as verified through retrospective immunostaining (data not shown).
As expected, we found that spine outgrowth increased in the presence of bicuculline for neurons transfected with EGFP alone (166% ± 13%, p < 0.05) or with EGFP and Rpt6-WT (161% ± 19%, p < 0.05) as compared to vehicle control (100% ± 11%; Figure 3B ). Remarkably, neurons transfected with EGFP and Rpt6-S120A did not show a bicuculline-dependent increase in new spine growth and instead showed a 44% decrease in spine outgrowth (56% ± 8%; p < 0.05; Figure 3B ), a level indistinguishable from the 55% decrease in outgrowth observed in vehicle-treated neurons expressing Rpt6-S120A (45% ± 5%; p = 0.4; Figure 3C ). Treatment of Rpt6-S120A transfected cells with lactacystin did not further depress spine outgrowth (50% ± 5%; Figure 3C ) compared to vehicle-treated Rpt6-S120A cells (p = 0.5), suggesting that the Rpt6-S120 residue is necessary for all proteasome-mediated spine outgrowth. Furthermore, treatment of Rpt6-S120A transfected cells with 30 mM CPP did not result in a further decrease in spine outgrowth (54% ± 6%; Figure 3C ) compared to untreated Rpt6-S120A controls (p = 0.2), suggesting that the S120A residue of Rpt6 is a key regulatory site for proteasome-and NMDA receptor-dependent facilitation of new spine growth.
Inhibition of CaMKII, but Not PKA, Decreases the Rate of New Spine Growth
Recent work has demonstrated that both PKA (Zhang et al., 2007) and CaMKIIa (Djakovic et al., 2009 ) are capable of phosphorylating the Rpt6 subunit of the proteasome at serine 120. In addition, CaMKIIa has been shown to mediate activity-dependent recruitment of proteasomes to dendritic spines (Bingol et al., 2010) , and phosphorylation of Rpt6 by CaMKIIa increases the rate of proteasomal degradation (Djakovic et al., 2012) . Finally, both CaMKII (Jourdain et al., 2003) and PKA (Kwon and Sabatini, 2011) have been implicated in activity-dependent spine outgrowth. We therefore chose to investigate the roles of CaMKII and PKA in activity-and proteasome-dependent new spine growth ( Figures 4A and 4B) . Inhibition of CaMKII with KN-93 (30 mM), which inhibits Ca 2+ -and CaM-dependent kinases, resulted in a 65% reduction in new spine growth (35% ± 6%) as compared to vehicle control (100% ± 11%; p < 0.001; Figure 4B ). In contrast, the rate of new spine outgrowth was not significantly different from vehicle controls (100% ± 20%) when PKA was inhibited with either myristoylated PKI 14-22 amide (5 mM; 104% ± 11%; p = 0.9; Figure 4B ) or Rp-cAMPS (20 mM; 120% ± 15%; p = 0.4; Figure 4B ). In order to examine whether CaMKII inhibition might reduce spine outgrowth through blocking phosphorylation of Rpt6-S120, we treated Rpt6-S120A-transfected neurons with KN-93. Spine outgrowth in Rpt6-S120A-transfected neurons treated with KN-93 (42% ± 8%; Figure 4B ) was not significantly different from KN-93-treated neurons (p = 0.8) or untreated Rpt6-S120A neurons (p = 0.7; Figure 3C ), suggesting that CaMKII and the proteasome act in the same pathway to regulate spine outgrowth. Moreover, the reduction in new spine growth observed after KN-93 treatment was not significantly different than that after lactacystin (p = 0.5; Figure 1C ) or CPP (p = 0.5; Figure 2G ) treatment. Thus, our data suggest that CaM-KII acts downstream of NMDA receptors to enhance local proteasomal activity via phosphorylation of the Rpt6 proteasomal subunit at serine 120.
Interaction of CaMKII with GluN2B Is Necessary for Activity-and Proteasome-Dependent Spine Outgrowth Because interrupting CaMKII binding to the NMDA receptor subunit GluN2B has been shown to decrease spine density (Gambrill and Barria, 2011) , we examined whether this interaction is important for activity-and proteasome-dependent spine growth using GluN2B-L1298A/R1300Q knockin (GluN2B KI) mice (Halt et al., 2012) . Both the L1298A and R1300Q mutations reduce GluN2B interaction with CaMKII by over 85% in vitro (Strack et al., 2000) , and these two mutations abrogate the activity-dependent increase in NMDA receptor-CaMKII interaction in vivo (Halt et al., 2012) . In order to determine whether interaction of CaMKII with GluN2B is necessary for activity-and proteasome-dependent spine outgrowth, we transfected hippocampal slice cultures from WT and GluN2B KI mice with EGFP and examined the consequences of treatment with bicuculline (30 mM) or lactacystin (10 mM) on rates of spine outgrowth (Figures 4C and 4D ). As expected, we found that treatment of WT mouse neurons with bicuculline resulted in a 50% increase in spine outgrowth (150% ± 14%) relative to vehicle-treated WT control neurons (100% ± 10%; p < 0.05; Figure 4D ). Remarkably, treatment with bicuculline did not alter outgrowth in GluN2B KI neurons (93% ± 6%) relative to vehicle-treated GluN2B KI controls (100% ± 11%; p = 0.6; Figure 4D ). Conversely, treatment with lactacystin reduced spine outgrowth in WT neurons by 69% (31% ± 6%) relative to vehicle-treated WT controls (100% ± 6%; p < 0.001), while GluN2B KI neurons were unaffected by lactacystin treatment (92% ± 12%) as compared to vehicletreated GluN2B KI controls (100% ± 21%; p = 0.8; Figure 4D ). Thus, we conclude that the interaction between CaMKII and GluN2B is necessary for activity-and proteasome-dependent spinogenesis.
Surprisingly, we found that baseline spine outgrowth on GluN2B KI control neurons was not different than that on WT control neurons (Table S1 ; p = 0.7). We predict that compensatory mechanisms are involved, whereby GluN2B KI mice experience an increase in activity-and proteasome-independent spine outgrowth. To further confirm this possibility, we tested the effect of blocking NMDA receptors with CPP on spine outgrowth in WT and GluN2B KI mice. As expected, we found that treatment with CPP reduced spine outgrowth on neurons from WT mice by 42% (58% ± 9%) relative to vehicle-treated WT control neurons (100% ± 10%, p < 0.05) but had no effect on neurons from GluN2B KI mice (96% ± 12%) relative to vehicle-treated GluN2B KI controls (100 ± 24, p = 0.9; Figure S4 ). These data support that spine outgrowth on GluN2B KI neurons is both activity and proteasome independent.
DISCUSSION
Pharmacological inhibition of the proteasome can lead to presynaptic, postsynaptic, and potentially circuit-wide effects (Bingol and Sheng, 2011; Tai and Schuman, 2008) . Which site or sites of action are relevant for activity-induced new spine growth? We observed that expression of Rpt6-S120A in individual neurons inhibited activity-induced spine outgrowth. Because this genetic manipulation was carried out in sparsely transfected neurons, and thus any nearby presynaptic neurons were untransfected, our results demonstrate that postsynaptic proteasomal function is necessary to facilitate new spine growth. In addition, because global pharmacological inhibition was not more effective at reducing spine outgrowth than overexpression of Rpt6-S120A in individual postsynaptic cells, our data also suggest that independent presynaptic and circuit-wide effects do not contribute significantly to the observed reduction in new spine growth. Finally, uncaging-induced spine outgrowth, which is independent of presynaptic activity, was also significantly reduced by blocking the proteasome, emphasizing the role of localized postsynaptic signaling. Our results strongly support a postsynaptic site of action for the proteasome in activityinduced new spine outgrowth.
How might synaptic activity and the proteasome act together to facilitate new spine growth? One possibility is that synaptic activity enhances proteasome function to cause the emergence of new spines. Alternatively, the synaptic stimulus could be the primary cause of spine outgrowth, and normal steady-state levels of proteasomal degradation are required for activityinduced new spine growth. We think that the latter possibility is unlikely because expression of Rpt6-S120A for 4 days does not produce any noticeable effects on cell health compared to untransfected neurons, suggesting that general proteasomal function is not significantly disrupted. In addition, the Rpt6-S120A mutation does not interfere with normal steady-state levels of proteasome-mediated protein degradation in heterologous cells (Djakovic et al., 2012) . Instead, because the Rpt6-S120A mutation blocks CaMKII-mediated enhancement of proteasomal degradation (Djakovic et al., 2012) , our data suggest that locally enhanced proteasomal degradation, probably through CaMKII phosphorylation of Rpt6 at S120, is required for activity-induced new spine growth. How might neural activity translate to enhanced local proteasomal degradation? Changes in neuronal activity have been shown to alter both proteasome activity (Bingol and Schuman, 2006; Djakovic et al., 2009 ) and localization (Bingol and Schuman, 2006; Bingol et al., 2010) . Although the relative contributions of changes in unit proteasome activity versus changes in proteasome localization to facilitating new spine outgrowth are not yet clear, our findings that spine outgrowth is reduced in mice with impaired NMDA receptor-CaMKII interaction support the possibility that relocation of the proteasome in response to activity may play a role in supporting new spine growth. In these GluN2B KI mice, activity-dependent association of CaMKII with the NMDA receptor is abrogated without altering CaMKII-T286 autophosphorylation, indicating that stimulus-induced activation of CaMKII is normal (Halt et al., 2012) . Thus, activity-dependent new spine growth could depend upon the local concentration of active proteasomes rather than stimulation of global proteasomal activity.
What target proteins are degraded by the proteasome in order to stimulate new spine growth? Due to the rapid reduction in spinogenesis observed with proteasome inhibition, we expect that the immediate protein targets normally act to inhibit spine outgrowth and are rapidly turned over in an activity-and proteasome-dependent manner. Although a large number of proteins have been shown to regulate spine morphology and dynamics, the most promising candidates for regulating new spine outgrowth are those associated with regulation of the spine actin cytoskeleton (Tashiro and Yuste, 2004; Tolias et al., 2011) . One promising candidate could be Ephexin5, a RhoA guanine nucleotide exchange factor shown to negatively regulate excitatory synapse formation (Margolis et al., 2010) . Another prime candidate could be Rap2, a member of the Ras family of GTPases. Rap2 overexpression causes a reduction in dendritic spine density (Ryu et al., 2008) , suggesting that it may be a negative regulator of spinogenesis. Both of these candidates are plausible targets of activity-induced upregulation of proteasomal activity; in each case, enhanced degradation would be expected to lead to increased spine density.
Malfunction of the proteasome (Tai and Schuman, 2008 ) and alterations in dendritic spine morphologies and densities (Bhatt et al., 2009 ) have independently been associated with neurological disorders resulting in mental retardation. Our data support a direct role for the proteasome in the activity-induced spinogenesis thought to be critical for normal brain function and for learning and memory. Disruption of proteasome-mediated degradation would be expected to interrupt activity-induced spine outgrowth during experience-dependent circuit modifications, suggesting one plausible mechanism by which proteasomal dysfunction may lead to neurological dysfunction.
EXPERIMENTAL PROCEDURES
Hippocampal Slice Culture and Transfection Hippocampal slices were prepared from postnatal day (P) 5-P7 SpragueDawley rats or wild-type or GluN2B KI mice (Halt et al., 2012) , as described (Stoppini et al., 1991) . Genes were delivered 2-5 days (EGFP alone) or 3-4 days (EGFP and Rpt6-WT or Rpt6-S120A) prior to imaging using biolistic gene transfer (180 PSI), as described (Woods and Zito, 2008) . We coated 1.6 mm gold beads with 10 mg of EGFP (Clontech) or with 10 mg EGFP and 25 mg HA-tagged Rpt6-WT or Rpt6-S120A (Djakovic et al., 2012) .
Time-Lapse Imaging and Image Analysis EGFP-transfected pyramidal neurons (5-12 days in vitro [DIV] ) were imaged at 29 C in ACSF using a custom two-photon microscope (Woods et al., 2011; Supplemental Experimental Procedures) . All images shown are maximum projections of three-dimensional (3D) stacks. Spine volumes, densities, and turnover rates were analyzed in 3D using custom software. Because spine addition rates can vary between cultures and experimental days, spine addition rates are reported as a percent of matched controls (calculated using all spines gained in the three posttreatment time points). Absolute spine addition and loss rates for all experiments are documented in Table S1 .
Pharmacology
We prepared 1,0003 stocks by dissolving MG132 (A.G. Scientific) and KN-93 (Tocris) in DMSO and bicuculline (Tocris), lactacystin (EMD Biochemicals), myristoylated PKI 14-22 amide (Tocris), Rp-cAMPS (Tocris), and CPP (Sigma) in water. Vehicle controls were matched in identity and volume to that in which the inhibitor was dissolved. When two drugs were applied, the vehicle consisted of the sum of the vehicles for both drugs.
Two-Photon Glutamate Uncaging-Induced Spine Outgrowth
Slices were imaged at 30 C in magnesium-free ACSF containing 5 mM MNI-caged-glutamate. Image stacks were acquired immediately before and after the uncaging stimulus, which consisted of 50 pulses (720 nm, 12 mW at the sample) of 4 ms duration delivered at 5 Hz by parking the beam at a point 0.5 mm from the edge of a secondary or tertiary apical dendrite. No more than four uncaging trials were performed on the same neuron. The success rate of de novo spine outgrowth was determined by two blind evaluators. Comparison of success rate across conditions was made by Fisher's exact test.
Statistics
Error bars represent standard error of the mean and significance was set at p = 0.05 (two-tailed t test, unless otherwise noted). All statistics were calculated across cells. *p < 0.05 and **p < 0.001.
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